P&G Focuses On Consumer Health, “Deemphasizes” Pharma
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble says consumer health trends are on its side as the company increases focus on its consumer health business and moves away from pharmaceuticals
You may also be interested in...
P&G Throws Weight Behind Consumer Growth After Shedding Pharma
Procter & Gamble faces several options - and some potential challenges - to grow its OTC portfolio using the resources gained in the sale of its prescription drug business
P&G Pharma Sale Could Bring $1 Billion To Feed Consumer Business
A sale of Procter & Gamble's pharma business could fetch about $1 billion, according to an estimate by one analyst. That represents cash P&G could reinvest in its core business areas, beauty and consumer health care, at a time when the recession is impacting growth and the credit crisis is forcing some retailers to cut inventories to conserve cash
Pfizer/Wyeth Merger Would Offer Diversification, Switch Outlet
Pfizer's potential acquisition of Wyeth could swing the company back to a diversified portfolio - including the return of a consumer health division -and help offset a dwindling pipeline and the looming generic competition that threatens Rx sales, analysts say